Toward a new gold standard for early safety: Automated temperature-controlled hERG test on the PatchLiner®

Frontiers in Pharmacology

Volumn 3 JAN, Issue , 2012, Pages

  Polonchuk, Liudmila ^a  

^a F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Automated patch clamp; hERG; Patchliner ; Physiological temperature

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ASTEMIZOLE; BEPRIDIL; CAPTOPRIL; CISAPRIDE; CLEMASTINE; DOFETILIDE; ERYTHROMYCIN; FLUOXETINE; GLIBENCLAMIDE; HALOPERIDOL; IBUPROFEN; MOXIFLOXACIN; OLANZAPINE; POTASSIUM CHANNEL HERG; QUINIDINE; SOTALOL; TAMOXIFEN; TERFENADINE; THIORIDAZINE; VERAPAMIL;

ACCURACY; ANIMAL CELL; ARTICLE; AUTOMATION; CHO CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG SAFETY; ELECTROPHYSIOLOGY; FEMALE; GOLD STANDARD; IC 50; INTERMETHOD COMPARISON; MEDICAL DEVICE; NONHUMAN; PATCH CLAMP; POTASSIUM CURRENT; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TEMPERATURE CONTROLLED AUTOMATED PATCH CLAMP SYSTEM; THERMOREGULATION; VOLTAGE CLAMP;

EID: 84865980135     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00003     Document Type: Article

References (16)

1. + channel block- ade by the fluoroquinolone antibi- otic moxifloxacin. Br. J. Pharmacol. 147, 905-916.
2. Du, C. Y., El Harchi, A., Zhang, Y. H., Orchard, C. H., and Hancox, J. C. (2011). Pharmacological inhibition of the HERG potassium channel is modulated by extracellular but not intracellular acidosis. J. Cardiovasc. Electrophysiol .22, 1163-1670.
3. Farre, C., Haythornthwaite, A., Haar- mann, C., Stoelzle, S., Kreir, M., George, M., Brüggemann, A., and Fertig, N. (2009). Port-a-patch and Patchliner: high fidelity electrophys- iology for secondary screening and safety pharmacology. Comb. Chem. High Throughput Screen. 12, 24-37.
4. Golden, A. P., Li, N., Chen, Q., Lee, T., Nevill, T., Cao, X., John- Son, J., Erdemli, G., Ionescu-Zanetti, C., Urban, L., and Holmqvist, M. (2011). IonFlux: a microfluidic patch clamp system evaluated with human ether-à-go-go related gene channel physiology and pharmacol- ogy. Assay Drug Dev. Technol. 9, 608-619.
5. Guthrie, H., Livingston, F. S., Gubler, U., and Garippa, R. (2005). A place for high-throughput electrophysiology in cardiac safety: screening hERG cell lines and novel compounds with the ion works HTTM system. J. Biomol. Screen. 10, 832-840.
6. International Conference on Harmon- isation. (2005). ICH S7B: the non- clinical evaluation of the poten- tial for delayed ventricular repo- larization (QT interval prolonga- tion) by human pharmaceuticals. CHMP/ICH/423/02. Fed. Regist. 70, 61133-61134.
7. Kirsch, G. E., Trepakova, E. S., Brime-Combe, J. C., Sidach, S. S., Erickson, H. D., Kochan, M. C., Shyjka, L. M., Lacerda, A. E., and Brown, A. M. (2004). Variability in the measurement of hERG potassium channel inhibition: effects of tem- perature and stimulus pattern. J. Pharmacol. Toxicol. Methods 50, 93-101.
8. Möller, C. (2010). Impact of new tech- nologies for cellular screening along the drug value chain. Drug Discov. Today 15, 384-390.
9. + channel. J. Mol. Cell Cardiol. 40, 107-118.
10. + channel block- ade by the antiarrhythmic agent dronedarone: resistance to muta- tions of the S6 residues Y652 and F656. Biochem. Biophys. Res. Com- mun. 325, 883-891.
11. Sanguinetti, M. C., and Tristani-Firouzi, M. (2006). hERG potassium chan- nels and cardiac arrhythmia. Nature 440, 463-469.
12. Swinney, D. C. (2009). The role of bind- ing kinetics in therapeutically use- ful drug action. Curr. Opin. Drug Discov. Devel. 12, 31-39.
13. + currents. Am. J. Physiol. Cell Physiol. 291, C165- C175.
14. Walker, B., Singleton, C., Bursill, J., Wyse, K., Valenzuela, S., Qiu, M., Breit, S., and Campbell, T. (1999). Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: affinity for open and inactivated states. Br. J. Pharmacol. 128, 444-450.
15. Yao, J. A., Du, X., Lu, D., Daharsh, E., and Atterson, P. (2005). Estimation of potency of hERG channel block- ers: impact of voltage protocol and temperature. J. Pharmacol. Toxicol. Methods 52, 146-153.
16. Yuill, K. H., Borg, J. J., Ridley, J. M., Milnes, J. T., Witchel, H. J., Paul, A. A., Kozlowski, R. Z., and Hancox, J. C. (2004). Potent inhibition of human cardiac potassium (HERG) channels by the anti-estrogen agent clomiphene-without QT interval prolongation. Biochem. Biophys. Res. Commun. 318, 556-561.